

Xuetian Yue

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/268565/publications.pdf>

Version: 2024-02-01

12
papers

386
citations

1040056

9
h-index

1199594

12
g-index

12
all docs

12
docs citations

12
times ranked

406
citing authors

#	ARTICLE	IF	CITATIONS
1	Zinc Fingers and Homeoboxes 2 Inhibits Hepatocellular Carcinoma Cell Proliferation and Represses Expression of Cyclins A and E. <i>Gastroenterology</i> , 2012, 142, 1559-1570.e2.	1.3	82
2	IL-6 promotes metastasis of non-small cell lung cancer by up-regulating TIM-4 via NF- κ B. <i>Cell Proliferation</i> , 2020, 53, e12776.	5.3	70
3	Tumor suppressor ZHX2 inhibits NAFLD-HCC progression via blocking LPL-mediated lipid uptake. <i>Cell Death and Differentiation</i> , 2020, 27, 1693-1708.	11.2	44
4	Gain-of-function mutant p53 activates small GTPase Rac1 through SUMOylation to promote tumor progression. <i>Genes and Development</i> , 2017, 31, 1641-1654.	5.9	35
5	ZHX2 enhances the cytotoxicity of chemotherapeutic drugs in liver tumor cells by repressing MDR1 via interfering with NF- κ B. <i>Oncotarget</i> , 2015, 6, 1049-1063.	1.8	33
6	Reduced nucleic ZHX2 involves in oncogenic activation of glypican 3 in human hepatocellular carcinoma. <i>International Journal of Biochemistry and Cell Biology</i> , 2014, 55, 129-135.	2.8	27
7	ZHX2 inhibits SREBP1c-mediated <i>de novo</i> lipogenesis in hepatocellular carcinoma via miR-24. <i>Journal of Pathology</i> , 2020, 252, 358-370.	4.5	27
8	Tumor suppressor p53 regulates intestinal type 2 immunity. <i>Nature Communications</i> , 2021, 12, 3371.	12.8	19
9	Multi-Omics Analysis of Fatty Acid Metabolism in Thyroid Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 737127.	2.8	18
10	NAD ⁺ salvage governs mitochondrial metabolism, invigorating natural killer cell antitumor immunity. <i>Hepatology</i> , 2023, 78, 468-485.	7.3	12
11	ZHX2 inhibits thyroid cancer metastasis through transcriptional inhibition of S100A14. <i>Cancer Cell International</i> , 2022, 22, 76.	4.1	11
12	SREBF2-STARD4 axis confers sorafenib resistance in hepatocellular carcinoma by regulating mitochondrial cholesterol homeostasis. <i>Cancer Science</i> , 2023, 114, 477-489.	3.9	8